Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	110.93	58.54	58.18	61.69	165.75	84.77
Short-Term Investments	143.6	312.17	508.68	388.56	387.13	276.82
Cash & Short-Term Investments	254.53	370.7	566.85	450.25	552.88	361.59
Cash Growth	-8.26%	-34.60%	25.90%	-18.56%	52.90%	-9.27%
Accounts Receivable	82.98	27.12	21.18	16.65	15.91	15.93
Other Receivables	1.5	2.3	4.6	1.9	0.9	17.14
Receivables	84.48	29.42	25.78	18.55	16.81	33.07
Inventory	5.55	6.2	9.41	4.52	7.31	7.61
Prepaid Expenses	26.55	10.39	14.74	10.13	5.82	8.14
Other Current Assets	-	-	-	2.99	-	-
Total Current Assets	371.11	416.7	616.78	486.44	582.83	410.41
Property, Plant & Equipment	15.78	19.63	25.54	30.05	34.3	35.09
Goodwill	0.75	0.75	0.75	0.75	0.94	0.94
Other Intangible Assets	108.68	103.22	103.69	96.32	147.5	153.19
Other Long-Term Assets	42.25	53.82	42.16	59.03	11.07	7.81
Total Assets	538.58	594.13	788.91	672.59	776.63	607.44
Accounts Payable	18.23	23.53	41.68	17.29	15.14	12.13
Accrued Expenses	105.76	86.03	107.57	95.74	75.18	56.79
Current Portion of Long-Term Debt	-	68.68	-	-	-	-
Current Portion of Leases	5.73	5.41	4.91	4.43	3.91	0.36
Current Unearned Revenue	-	2.82	7.1	11.98	16.27	-
Other Current Liabilities	5.35	14.29	16.66	12.72	13.59	23.38
Total Current Liabilities	135.07	200.75	177.91	142.16	124.09	92.66
Long-Term Debt	311.37	310.31	377.26	375.55	226.58	215.34
Long-Term Leases	12.65	17.19	22.61	27.51	31.5	28.34
Long-Term Unearned Revenue	-	-	1.84	10.93	20.38	-
Other Long-Term Liabilities	5.93	6.8	8.49	73.59	71.98	59.89
Total Liabilities	465.02	535.05	588.1	629.73	474.52	396.23
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,550	1,506	1,328	1,060	1,069	797.99
Retained Earnings	-1,475	-1,447	-1,126	-1,014	-765.97	-585.88
Comprehensive Income & Other	-1.05	-0.08	-1.46	-2.91	-0.56	-0.9
Shareholders' Equity	73.56	59.08	200.81	42.85	302.11	211.21
Total Liabilities & Equity	538.58	594.13	788.91	672.59	776.63	607.44
Total Debt	329.75	401.58	404.78	407.49	261.99	244.03
Net Cash (Debt)	-75.22	-30.88	162.07	42.76	290.9	117.56
Net Cash Growth	-	-	279.04%	-85.30%	147.45%	-39.30%
Net Cash Per Share	-0.86	-0.39	2.18	0.67	4.86	2.47
Filing Date Shares Outstanding	89.47	88.74	76.1	64.74	63.21	60.24
Total Common Shares Outstanding	89.46	87.45	75.37	64.29	62.49	52.25
Working Capital	236.04	215.95	438.87	344.27	458.74	317.75
Book Value Per Share	0.82	0.68	2.66	0.67	4.83	4.04
Tangible Book Value	-35.87	-44.9	96.37	-54.22	153.68	57.09
Tangible Book Value Per Share	-0.40	-0.51	1.28	-0.84	2.46	1.09
Machinery	-	4.72	5.06	4.99	4.73	2.39
Construction In Progress	-	-	0.17	0.08	0.63	6.34
Leasehold Improvements	-	9.37	9.69	9.18	8.79	4.63

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q